Syncona

Syncona is a FTSE250 company focused on founding, building, and funding healthcare companies. They aim to deliver transformational treatments for patients in areas of high unmet need, building a diversified portfolio of 20-25 globally leading life science businesses.

Offices: London (United Kingdom), St. Peter Port (Guernsey)

Investment Stages: Series A, Series B, Series C

Markets: Oncology, Ophthalmology, Cell therapy, Gene therapy, Renal, Cardioprotection, Immunology, Rare diseases

Founded Year: 2012

Investor Type: Venture Capital

Portfolio Companies: Autolus Therapeutics, Beacon Therapeutics, iOnctura, Spur Therapeutics, Quell Therapeutics, Anaveon, Resolution Therapeutics, Purespring Therapeutics, Forcefield Therapeutics, OMass Therapeutics, Mosaic Therapeutics, Kesmalea Therapeutics, Yellowstone Biosciences, Slingshot Therapeutics, Gyroscope Therapeutics, Blue Earth, Nightstar, Neogene Therapeutics, 14MG, Azeria Therapeutics, Clade Therapeutics

Website: https://www.synconaltd.com

Team Page: https://www.synconaltd.com/our-people/

Portfolio Link: https://www.synconaltd.com/portfolio/

LinkedIn: https://www.linkedin.com/company/syncona-partners-llp/

Twitter: https://twitter.com/synconaltd?lang=en

Instagram:

Crunchbase: https://www.crunchbase.com/organization/syncona-partners-llp

Pitchbook: https://pitchbook.com/profiles/investor/60285-52